Labatec pharma announces an exclusive licensing agreement signed with aft pharmaceuticals, to commercialise MAXIGESIC IV®, in Switzerland
29 mars 2023
LABATEC PHARMA ANNOUNCES AN EXCLUSIVE LICENSING AGREEMENT SIGNED WITH AFT PHARMACEUTICALS, TO COMMERCIALISE MAXIGESIC IV®, IN SWITZERLAND Geneva, March 27, 2023 – Labatec Pharma SA (Labatec) signed a new licensing agreement with AFT Pharmaceuticals (NZX.AFT, ASX.AFP), for the exclusive rights to commercialise Maxigesic IV® in Switzerland, a treatment for mild to moderate pain for use […]